<DOC>
	<DOCNO>NCT03046979</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety apatinib patient advance HCC .</brief_summary>
	<brief_title>Study Apatinib Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) common primary malignant tumor liver . It lack effective drug systemic treatment HCC . Currently , Sorafenib choice approve FDA advance HCC , although prolongs survival less 3 month . The treatment advance HCC still long way go . At present , relevant phase II phase III clinical study apatinib advanced HCC ongoing . Based important discovery previous clinical study , intend enlarge sample size make observation efficacy safety apatinib patient advance HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Before research step , patient 's informed consent must obtain first . 2 . The diagnosis HCC : histologic diagnosis Alpha fetoprotein ( AFP ) two kind image diagnosis . 3 . Patients Barcelona stage ( BCLC ) C firstline treatment failure non tolerance sorafenib . 4 . Ages 18 75 year old . 5 . ChildPugh score 57 point , patient ChildPugh 7 point without ascites . 6 . Eastern Cooperative Oncology Group performance score ( ECOG PS ) 01 point . 7 . Adequate organ function meeting follow : Hemoglobin ( HBG ) ≧9.0g/dl Neutrophil count ( ANC ) ≧1,500/mm3 Platelet count ( PLT ) ≧50,000/ul Total bilirubin ( TBIL ) &lt; 2mg/dL ( 3mg/dL , ChildPugh B ) Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &lt; 5×ULN ( upper limit normal ) ALP ( alkaline phosphatase ) &lt; 4×ULN PT ( prothrombin time ) &gt; 50 % PTINR &lt; 2.3 , &lt; 6 second great control 8 . For patient take warfarin , least week close monitoring patient , , accord standard treatment , every time medication , subject ' INR measurement stable 9 . SCr ( serum creatinine ) &lt; 1.5×ULN 10 . For pregnant woman , result serum pregnancy test must negative within 14 day initiation treatment . 11 . All men woman participate study take reliable contraceptive measure within trial two week trial . 1 . Patients ChildPugh 7 serious uncontrolled ascites . 2 . Patients serious cardiovascular disease . 3 . Patients high blood pressure unable control . 4 . Patients history HIV ( human immunodeficiency virus ) infection . 5 . Active clinical severe infection ( &gt; 2 , NCICTCAE version 3 ) . 6 . Need drug treatment patient epilepsy ( steroid antiepileptic drug ) 7 . Has history allogeneic organ transplantation . 8 . Patients history physical sign bleed . 9 . Patients undergoing renal dialysis . 10 . Metastatic liver cancer . 11 . Patients uncontrollable ascites . 12 . Patients encephalopathy . 13 . Patients history gastrointestinal bleeding period 30 day join study . 14 . Patients history esophagus varicosity burst hemorrhage , effective treatment therapy prevent recurrence bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>apatinib</keyword>
	<keyword>advanced hepatocellular carcinoma</keyword>
</DOC>